Pancreatic cancer jAK2 and STAT3 dual targeting inhibitor containing phenoxy acetyl hydrazine compound and application

By developing a dual-targeting inhibitor of JAK2 and STAT3 in pancreatic cancer containing a phenoxyacetylhydrazine structure, the problem of slow treatment strategies for pancreatic cancer in existing technologies has been solved. This approach achieves dual inhibition of JAK2 and STAT3, significantly inhibiting tumor proliferation and migration, and exhibits good safety and therapeutic efficacy.

CN116251099BActive Publication Date: 2026-07-24LANZHOU UNIV SECOND HOSPITAL
0 Cites 0 Cited by

Patent Information

Application Number
CN202310482444.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-30
Publication Date
2026-07-24
Estimated Expiration
2043-04-30

AI Technical Summary

Technical Problem

The lack of effective drugs for treating pancreatic cancer in the current technology, especially targeted inhibitors of the STAT3-related signaling pathway, has led to slow development of pancreatic cancer treatment strategies, and few existing drugs have been proven effective in experimental trials.

Method used

Develop compounds containing phenoxyacetylhydrazine structure as dual-target inhibitors of JAK2 and STAT3 in pancreatic cancer. By inhibiting the phosphorylation of JAK2 and STAT3, these compounds can arrest the cell cycle, inhibit tumor proliferation and migration, and promote apoptosis. They can be applied to pharmaceutical formulations such as tablets, capsules, syrups, suspensions, and injections.

Benefits of technology

This compound can significantly inhibit the activation of JAK2 and STAT3 in pancreatic cancer cells, reduce drug resistance, improve treatment efficacy, reduce toxic side effects, and has good safety and broad inhibitory effects. It significantly inhibits tumor proliferation, migration and angiogenesis, and promotes cell apoptosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a pancreatic cancer JAK2 and STAT3 dual-target inhibitor containing a phenoxy acetic hydrazine compound and application thereof, and the dual-target inhibitor comprises a compound containing a phenoxy acetic hydrazine structure. The dual-target inhibitor comprises a pharmaceutically acceptable salt. The pancreatic cancer JAK2 and STAT3 dual-target inhibitor containing the phenoxy acetic hydrazine compound is applied to the preparation of a drug for treating pancreatic cancer. The drug has a new use in treating pancreatic cancer by inhibiting tumor proliferation, migration and invasion, angiogenesis, epithelial mesenchymal transition, blocking a cell cycle and promoting cell apoptosis. The pharmaceutical preparation of the drug composition comprises tablets, capsules, syrup, suspensions and injections. A drug for treating pancreatic cancer comprises the pancreatic cancer JAK2 and STAT3 dual-target inhibitor containing the phenoxy acetic hydrazine compound and a pharmaceutically acceptable carrier. The application has the beneficial effect that the pancreatic cancer JAK2 and STAT3 have a better inhibiting effect, the experimental results show that the inhibiting effect is good, the application prospect is wider, and the safety is better.
Need to check novelty before this filing date? Find Prior Art